BioLoomics Inc.
The University of Colorado Connection
BioLoomics was founded in 2019 by Doug Chapnik , an alum of biochemistry at CU Boulder and a graduate of the laboratory of Xuedong Liu , professor of biochemistry at CU Boulder. BioLoomics is developing next-generation Antibody Drug Conjugates (ADCs) for safer, more effective cancer therapies.
Funding Status and Investment Opportunities
- Industry Applications: Health and Wellness, Biotech, Therapeutics
- Funding Round: Seed A
- Contact for Investment Inquiries: Doug Chapnik , dougchapnick@bioloomics.com
In the News
- BioLoomics raises $8.7M in seed financing (2023)
- Boulder Valley bioscience sector experiencing bounceback (2020)
- Colorado university and lab ventures to be showcased at second annual Destination Startup (2020)
- Six CU Boulder startups clean up at Advanced Industries Accelerator competition, winning $1.5M in grants (2019)
Technology Development Funding
U.S. Defense Advanced Research Projects Agency (DARPA)
This page was last updated on Sept. 10, 2026. Please email vpnews@colorado.edu for corrections or updates
The Insider Investor Newsletter
Media Inquiries
For marketing inquiries and news tips, contact Daniel Leonard, senior marketing and communications specialist for Venture Partners at CU Boulder.
For media inquiries, please visit colorado.edu/news/formedia.